A Multi-Center Study Evaluating the Safety of AC-170 0.24%

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aciex Therapeutics, Inc.
• Treatments: Cetirizine

Criteria

Inclusion Criteria:

• at least 2 years of age

• be able to self-administer eye drops or have a parent/legal guardian available for this purpose

• if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis)

• have ocular health within normal limits

Exclusion Criteria:

• known contraindications or sensitivities to the study medication or its components

• any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters

• use of disallowed medication during the period indicated prior to the enrollment or during the study